Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring

Developments and future prospects

Shahrokh F. Shariat, Jose A. Karam, Jay Raman

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Bladder cancer is currently diagnosed using cystoscopy and cytology in patients with suspicious signs and symptoms. These tests are also used to monitor patients with a history of bladder cancer. The recurrence rate for bladder cancer is high, thus necessitating long-term follow-up. Urine cytology has a high sensitivity and specificity for the detection of high-grade urothelial carcinoma, but lacks the sensitivity to detect low-grade tumors. Recently, multiple noninvasive urine-based bladder cancer tests have been developed. Many markers (BTA stat®, BTA TRAK®, ImmunoCyt™, NMP22® and UroVysion™) have already been approved by the US FDA for bladder cancer surveillance, while other markers are still undergoing development, preclinical and clinical investigation. An ideal bladder cancer test would be noninvasive, highly sensitive and specific, inexpensive, easy to perform and yield highly reproducible results. Many of the tests reviewed herein meet some, but not all, of these criteria.

Original languageEnglish (US)
Pages (from-to)165-180
Number of pages16
JournalBiomarkers in Medicine
Volume2
Issue number2
DOIs
StatePublished - Apr 1 2008

Fingerprint

Cytology
Urinary Bladder Neoplasms
Cell Biology
Urinary Bladder
Urine
Carcinoma
Monitoring
Tumors
Cystoscopy
Signs and Symptoms
Recurrence
Sensitivity and Specificity
nuclear matrix protein 22

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry
  • Biochemistry, medical
  • Drug Discovery

Cite this

@article{6e6e19a0afb041f2b8cd91d78b818bd8,
title = "Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: Developments and future prospects",
abstract = "Bladder cancer is currently diagnosed using cystoscopy and cytology in patients with suspicious signs and symptoms. These tests are also used to monitor patients with a history of bladder cancer. The recurrence rate for bladder cancer is high, thus necessitating long-term follow-up. Urine cytology has a high sensitivity and specificity for the detection of high-grade urothelial carcinoma, but lacks the sensitivity to detect low-grade tumors. Recently, multiple noninvasive urine-based bladder cancer tests have been developed. Many markers (BTA stat{\circledR}, BTA TRAK{\circledR}, ImmunoCyt™, NMP22{\circledR} and UroVysion™) have already been approved by the US FDA for bladder cancer surveillance, while other markers are still undergoing development, preclinical and clinical investigation. An ideal bladder cancer test would be noninvasive, highly sensitive and specific, inexpensive, easy to perform and yield highly reproducible results. Many of the tests reviewed herein meet some, but not all, of these criteria.",
author = "Shariat, {Shahrokh F.} and Karam, {Jose A.} and Jay Raman",
year = "2008",
month = "4",
day = "1",
doi = "10.2217/17520363.2.2.165",
language = "English (US)",
volume = "2",
pages = "165--180",
journal = "Biomarkers in Medicine",
issn = "1752-0363",
publisher = "Future Medicine Ltd.",
number = "2",

}

Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring : Developments and future prospects. / Shariat, Shahrokh F.; Karam, Jose A.; Raman, Jay.

In: Biomarkers in Medicine, Vol. 2, No. 2, 01.04.2008, p. 165-180.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring

T2 - Developments and future prospects

AU - Shariat, Shahrokh F.

AU - Karam, Jose A.

AU - Raman, Jay

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Bladder cancer is currently diagnosed using cystoscopy and cytology in patients with suspicious signs and symptoms. These tests are also used to monitor patients with a history of bladder cancer. The recurrence rate for bladder cancer is high, thus necessitating long-term follow-up. Urine cytology has a high sensitivity and specificity for the detection of high-grade urothelial carcinoma, but lacks the sensitivity to detect low-grade tumors. Recently, multiple noninvasive urine-based bladder cancer tests have been developed. Many markers (BTA stat®, BTA TRAK®, ImmunoCyt™, NMP22® and UroVysion™) have already been approved by the US FDA for bladder cancer surveillance, while other markers are still undergoing development, preclinical and clinical investigation. An ideal bladder cancer test would be noninvasive, highly sensitive and specific, inexpensive, easy to perform and yield highly reproducible results. Many of the tests reviewed herein meet some, but not all, of these criteria.

AB - Bladder cancer is currently diagnosed using cystoscopy and cytology in patients with suspicious signs and symptoms. These tests are also used to monitor patients with a history of bladder cancer. The recurrence rate for bladder cancer is high, thus necessitating long-term follow-up. Urine cytology has a high sensitivity and specificity for the detection of high-grade urothelial carcinoma, but lacks the sensitivity to detect low-grade tumors. Recently, multiple noninvasive urine-based bladder cancer tests have been developed. Many markers (BTA stat®, BTA TRAK®, ImmunoCyt™, NMP22® and UroVysion™) have already been approved by the US FDA for bladder cancer surveillance, while other markers are still undergoing development, preclinical and clinical investigation. An ideal bladder cancer test would be noninvasive, highly sensitive and specific, inexpensive, easy to perform and yield highly reproducible results. Many of the tests reviewed herein meet some, but not all, of these criteria.

UR - http://www.scopus.com/inward/record.url?scp=44449084353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449084353&partnerID=8YFLogxK

U2 - 10.2217/17520363.2.2.165

DO - 10.2217/17520363.2.2.165

M3 - Review article

VL - 2

SP - 165

EP - 180

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

SN - 1752-0363

IS - 2

ER -